Pregabalin vs. Opioids for the treatment of neuropathic cancer pain: A prospective, head-to-head, randomized, open-label study

Pain Practice

Volumn 14, Issue 1, 2014, Pages 32-42

  Raptis, Efklidis ^a   Vadalouca, Athina ^a   Stavropoulou, Evmorfia ^a   Argyra, Eriphili ^a   Melemeni, Aikaterini ^a   Siafaka, Ioanna ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adjuvants; Cancer pain; Fentanyl; Neuropathic; Neuropathic cancer pain; Opioids; Pregabalin

Indexed keywords

CODEINE; FENTANYL; METHADONE; METHYLPREDNISOLONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREGABALIN;

ADULT; ANALGESIA; ARTICLE; CANCER PAIN; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUROPATHIC CANCER PAIN; NEUROPATHIC PAIN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SUSTAINED DRUG RELEASE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS; CANCER PAIN; FENTANYL; NEUROPATHIC; NEUROPATHIC CANCER PAIN; OPIOIDS; PREGABALIN;

AGED; ANALGESICS, OPIOID; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEURALGIA; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84891626217     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12045     Document Type: Article

References (64)

1. Grond S, Zech D, Diefenbach C, et al. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64:107-114.
2. Caraceni A, Portenoy RK. IASP task force on cancer pain an international survey of cancer pain characteristics and syndromes. Pain. 1999;82:263-274.
3. García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients: results of the on study. Ann Oncol. 2011;22(4):924-930.
4. Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2010;153:359-365.
5. Tofthagen CS, McMillan SC. Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer. Cancer Nurs. 2010;33(6):436-444.
6. Urch CE, Dickenson AH. Neuropathic pain in cancer. Eur J Cancer. 2008;44:1091-1096.
7. World Health Organization. Cancer Pain Relief. Geneva: Office of Publications; WHO, 1986.
8. World Health Organization. Cancer Pain Relief, 2nd edn, with a guide to opioid availability. Geneva: WHO; 1996.
9. Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59:850-856.
10. Grond S, Radbruch L, Meuser T, et al. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79:15-20.
11. Mishra S, Bhatnagar S, Gupta D, et al. Management of neuropathic cancer pain following WHO analgesic Ladder: a prospective study. Am J Hosp Palliat Care. 2010;25(6):447-451.
12. Cherny NI, Thaler HT, Friedlander-Klars H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology. 1994;44:857-861.
13. Dellemijn P. Are opioids effective in relieving neuropathic pain? Pain. 1999;80(3):453-462.
14. Eisenberg E, McNicol ED, Barr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of non-malignant origin: systematic review and Meta-analysis of randomized controlled trials. JAMA. 2005;293(24):3043-3052.
15. Mercadante S, Gebbia V, David F, et al. Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J Pain. 2009;10(6):594-600.
16. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223-1232.
17. Vondracek P, Oslejskova H, Kepak T, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13:332-336.
18. Matsuoka H, Makimura C, Koyama A, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res. 2012;32(5):1805-1809.
19. Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29(3):177-82.
20. Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care. 2010;29(1):70-79.
21. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909-2917.
22. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: a systematic review. Palliat Med. 2011;25(5):553-559.
23. Ripamonti CI, Bandieri E, Roila F. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol. 2011;22(suppl 6):vi69-vi77.
24. Virizuela JA, Escobar Y, Cassinello J, et al. Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clin Transl Oncol. 2012;14:499-504.
25. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;8(3):CD007076.
26. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-1123.
27. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573-581.
28. European Commission, Community Register of Medicinal Products for Human Use. 2011. Lyrica, Summary Of Product Characteristics. http://ec.europa.eu/health/documents/community-register/html/h279.htm. (accessed August 30, 2012).
29. Brysson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996;8:459-476.
30. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805-1815.
31. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12(8):1040-1046.
32. Boureau F, Doubrère JF, Luu M. Study of verbal description in neuropathic pain. Pain. 1990;42(2):145-152.
33. Attal N, Bouhassira D. Can pain be more or less neuropathic? Pain. 2004;110:510-511.
34. Rasmussen PV, Sindrup SH, Jensen TS, et al. Symptoms and signs in patients with suspected neuropathic pain. Pain. 2004;2:461-469.
35. Bennett MI, Smith BH, Torrance N, et al. Can pain be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians Pain. 2006;122:289-294.
36. Hansson P. Diagnostic work-up of neuropathic pain: computing, using questionnaires or examining the patient? Eur J Pain. 2007;11:367-369.
37. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
38. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist. 2010;15(Suppl 2):13-18.
39. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17(8):1010-1018.
40. Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain. 2011;3(Suppl):S74-S83.
41. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14-27.
42. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;2:29-36.
43. Van SR, Vos C, Meerding W, et al. Linguistic validation of the DN4 for use in international studies. Eur J Pain. 2010;14(1):58-63.
44. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function Pain. 1995;61(2):277-284.
45. Li KK, Harris K, Hadi S, et al. What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med. 2007;10(6):1338-1346.
46. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27(1):117-126.
47. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain. 2000;88(3):287-294.
48. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158.
49. Caraceni A, Hanks G, Kaasa S, et al. European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-e68.
50. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1998;33:11-23.
51. Martin LA, Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes and clinical controversies. J Pain Symptom Manage. 1997;14(2):99-117.
52. Smith HS, Meek PD. Pain responsiveness to opioids: central versus peripheral neuropathic pain. J Opioid Manag. 2011;7(5):391-400.
53. Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145-161.
54. Vadalouca A, Raptis E, Moka E, et al. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract. 2012;12(3):219-251.
55. Anastassiou E, Iatrou CA, Vlaikidis N, et al. ATLAS investigators. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Invest. 2011;31(6):417-426.
56. Stacey BR, Swift JN. Pregabalin for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep. 2006;10:179-184.
57. Tzellos TG, Papazisis G, Amaniti E, Kouvelas D. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. Eur J Clin Pharmacol. 2008;64:851-858.
58. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417-442.
59. Mańas A, Ciria JP, Fernández MC, et al. Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health. Clin Transl Oncol. 2011;13(9):656-663.
60. Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30(7):2927-2933.
61. Agarwal S, Polydefkis M, Block B, et al. Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. Pain Med. 2007;8(7):554-562.
62. Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Invest. 2007;27(1):75-83.
63. Tassinari D, Drudi F, Rosati M, et al. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med. 2011;25(5):410-423.
64. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.